An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Mirum Pharmaceuticals, Inc. (MIRM) will report Q4 and year-end 2023 financial results on February 28, 2024, followed by a conference call to discuss financial results and corporate progress. Details for the call provided.
Positive
None.
Negative
None.
FOSTER CITY, Calif.--(BUSINESS WIRE)--
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2023 financial results on Wednesday, February 28, 2024. Mirum will also host a conference call to discuss the fourth quarter and year-end 2023 financial results and recent corporate progress.
Conference call details:
Wednesday, February 28, 2024
4:30 p.m. ET / 1:30 p.m. PT
You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in Canada. Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months of age and older and in Europe in PFIC for patients two months of age and older. Cholbam is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme defects and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. Chenodal has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, Chenodal, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX.
When will Mirum Pharmaceuticals report its Q4 and year-end 2023 financial results?
Mirum Pharmaceuticals will report its Q4 and year-end 2023 financial results on Wednesday, February 28, 2024.
What time is the conference call to discuss the financial results scheduled for?
The conference call to discuss the financial results is scheduled for 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, February 28, 2024.
How can one access the conference call?
To access the conference call, you can dial U.S./Toll-Free: +1 833 470 1428 or International: +1 404 975 4839 with the Passcode: 089049. Alternatively, you can access the call via webcast on Mirum's website.
Will there be a replay of the webcast available?
Yes, a replay of the webcast will be available for 30 days after the call.
mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
